Celldex Therapeutics Risk Adjusted Performance
| CLDX Stock | | | USD 32.28 -1.69 -4.97% |
Risk-Adjusted Performance (RAP) measures the return an equity would have generated if it carried the same total risk (standard deviation) as the market. Derived from the Sharpe Ratio, RAP is expressed in percentage terms, making direct comparison across assets with different volatility profiles straightforward. Below is Celldex Therapeutics's current Risk Adjusted Performance with peer comparisons and related risk metrics.
Current Risk Adjusted Performance Value
Celldex Therapeutics has a Risk Adjusted Performance of 0.1474, indicating positive but modest risk-adjusted return. Celldex Therapeutics has produced a positive return relative to risk, though the margin is limited.
RAP | = | (ER[a] - RFR) * STD[b])/STD[b]RFR |
| = | 0.1474 | |
Risk Adjusted Performance Peers Comparison
Celldex Therapeutics falls above the 0.04 peer average for Risk Adjusted Performance. Spyre Therapeutics leads at 0.2916 while Harmony Biosciences Holdings registers the lowest at -0.0666. Celldex Therapeutics's risk-adjusted return exceeds the peer average, indicating more efficient compensation for risk taken.
Risk Adjusted Performance Relative To Other Indicators
The chart below plots Risk Adjusted Performance against Maximum Drawdown for Celldex Therapeutics and its peers. Each point represents one equity — position along the horizontal axis shows Risk Adjusted Performance while the vertical axis shows Maximum Drawdown. Equities that cluster in different quadrants carry distinct risk-return profiles. Use the dropdowns to swap in other indicators for either axis.
Celldex Therapeutics's Maximum Drawdown of
28.64 runs about
194.31 times its Risk Adjusted Performance of
0.15 . This indicates Maximum Drawdown substantially exceeds Risk Adjusted Performance for Celldex Therapeutics.
Methodology, Assumptions & Data Sources
Celldex Therapeutics has a current Risk Adjusted Performance reading of 0.1474. The Risk Adjusted Performance for Celldex Therapeutics applies a standardized calculation to daily closing prices and, where applicable, volume data across the selected period. All inputs are based on exchange-reported closing prices, with adjustments for stock splits, dividends, and other corporate actions. Celldex Therapeutics operates in the health care sector, which may exhibit distinct volatility and momentum characteristics relative to the broader market. Results are based on historical returns and do not predict future performance. This indicator is provided for informational purposes.
Other Technical Indicators